Atuka provides contract research and consultancy services for the biopharmaceutical industry with world-leading expertise in Parkinson’s disease and related neurological conditions. We provide cutting-edge, rodent and non-human primate models (toxin and molecular pathology-driven) to evaluate efficacy and target engagement over a comprehensive range of symptomatic, motor (e.g. parkinsonism and dyskinesia), non-motor (e.g. cognition and impulse control) and disease-modification assays. Atuka also offers medicinal chemistry, DMPK and in-vivo imaging services to aid development of novel therapeutics.
PPD® Biotech is devoted to finding the right Phase I-IV clinical development solutions for biotech and small to midsize pharma. With dedicated teams, PPD Biotech combines the global resource scalability and full-service offerings of PPD with personal attention, flexibility and a shared mindset that enables us to find the optimal solutions for your study, no matter the size.
We bring a comprehensive set of expertise to gene therapy research – from product development and regulatory strategists, labs services and clinical execution through to pre- and post-approval work. We have the right science, trial designs and experienced operations teams to move your gene therapy studies forward.
We provide contract development and manufacturing services that enable pharma and biotech companies to deliver medicines to patients. From the building blocks of life to the final drug product, our solutions are created to simplify your outsourcing experience and provide a reliable outcome when you expect it. Our extensive track record includes commercialization of pioneering therapies and manufacturing of a wide variety of therapies. Together, let’s bring the next medicine to life.
NeuExcell Therapeutics is a gene therapy company leading neural regeneration and repair. NeuExcell has generated robust pre-clinical data that demonstrate the in vivo potential of their innovative technology to regenerate functional brain tissue that has been damaged in a variety of neurodegenerative conditions such as stroke, Huntington’s disease, ALS, and Alzheimer’s disease. NeuExcell’s experienced management team is well-positioned to progress this exciting technology and is seeking investors to support the advancement of IND-enabling studies and first-in-human clinical trials.
Founded in 2008, Invicro’s mission is to improve the role and function of imaging in drug discovery across all therapeutic areas and phases. As part of the Konica Minolta Precision Medicine Initiative, we combine operational excellence with scientific, medical and analytic expertise to de-risk drug development from preclinical to late phase. The company’s innovative quantitative tissue biomarker services help uncover novel insights and support the development of more personalized therapies.